4/24/2015

Orion upgrades full-year outlook for 2015

ORION CORPORATION      STOCK EXCHANGE RELEASE 24 APRIL 2015 at 9.25 A.M. EEST              


Orion upgrades full-year outlook for 2015


Orion Corporation upgrades the full-year outlook estimate for 2015 provided on 4 February 2015. Operating profit of the first quarter was EUR 83 million which is 23 % higher than in the previous year. Based on the good start for the year the company estimates that the full-year operating profit will be higher than estimated previously.

New full-year outlook estimate for 2015, provided on 24 April 2015

Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014).

Operating profit is estimated to exceed EUR 230 million.

The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014)

Previous full-year outlook estimate for 2015, provided on 4 February 2015

Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014).

Operating profit is estimated to exceed EUR 200 million.

The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014)

Orion will publish the Interim Report January-March 2015 on Wednesday, 29 April 2015.

  
Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

                                                                       
Contact person:
Jari Karlson, CFO
tel. +358 10 426 2883

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.